Ed­i­tas los­es its lead in the biotech race to launch the first CRISPR/Cas9 hu­man study

Ed­i­tas was the first of three gene edit­ing biotechs to make a splash on Nas­daq and up un­til this week it al­so looked like it was in the lead in the race to be the first in the group to make it in­to a ground­break­ing hu­man study.

No more.

On Mon­day Ed­i­tas $ED­IT CEO Ka­trine Bosley said that a “man­u­fac­tur­ing de­lay re­lat­ed to pro­duc­tion of in­put ma­te­ri­als for AAV man­u­fac­tur­ing” forced the com­pa­ny to de­lay their planned IND fil­ing to the mid­dle of next year. As ex­ecs ex­plained it, one of the in­put ma­te­ri­als used in mak­ing their de­liv­ery ve­hi­cle failed a qual­i­ty con­trol in­spec­tion, and the de­lay in fix­ing that caused them to lose their time slot with the CMO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.